{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:31:20Z","timestamp":1761744680074},"reference-count":186,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Cl\u00ednica"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.medcli.2017.11.037","type":"journal-article","created":{"date-parts":[[2018,1,19]],"date-time":"2018-01-19T05:56:50Z","timestamp":1516341410000},"page":"39.e1-39.e17","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Recomendaciones de GESIDA\/PETHEMA sobre el diagn\u00f3stico y tratamiento de los linfomas en pacientes infectados por el virus de la inmunodeficiencia humana"],"prefix":"10.1016","volume":"151","author":[{"given":"Pilar","family":"Miralles","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Tom\u00e1s","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Berenguer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"G\u00f3mez Codina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mi","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"D\u00edez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvador","family":"Vill\u00e0","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Men\u00e1rguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9-Mar\u00eda","family":"Ribera Santasusana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medcli.2017.11.037_bib0935","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/jama.1993.03500060023008","article-title":"From the Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults","volume":"269","year":"1993","journal-title":"JAMA."},{"key":"10.1016\/j.medcli.2017.11.037_bib0940","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1093\/jnci\/92.22.1823","article-title":"Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults","volume":"92","year":"2000","journal-title":"J Natl Cancer Inst."},{"key":"10.1016\/j.medcli.2017.11.037_bib0945","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jnci\/djt158","article-title":"Temporal trends in presentation and survival for HIV-associated lymphoma in the antiretroviral therapy era","volume":"105","author":"Gopal","year":"2013","journal-title":"J Natl Cancer Inst."},{"key":"10.1016\/j.medcli.2017.11.037_bib0950","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1182\/blood-2011-08-373738","article-title":"How I treat HIV-associated lymphoma","volume":"119","author":"Dunleavy","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib0955","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/QAI.0b013e31802bb5d0","article-title":"Prognosis of AIDS-related systemic non-Hodgkin lymphoma treated with chemotherapy and highly active antiretroviral therapy depends exclusively on tumor-related factors","volume":"44","author":"Miralles","year":"2007","journal-title":"J Acquir Immune Defic Syndr."},{"key":"10.1016\/j.medcli.2017.11.037_bib0960","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1200\/JCO.2004.11.097","article-title":"Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma","volume":"22","author":"Stebbing","year":"2004","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib0965","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2141.2004.04934.x","article-title":"Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease","volume":"125","author":"Hoffmann","year":"2004","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2017.11.037_bib0970","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/00002030-200301030-00011","article-title":"Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy","volume":"17","author":"Gerard","year":"2003","journal-title":"AIDS."},{"key":"10.1016\/j.medcli.2017.11.037_bib0975","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1157\/13116574","article-title":"Recomendaciones de GESIDA\/PETHEMA sobre el diagn\u00f3stico y el tratamiento de los linfomas en pacientes infectados por el virus de la inmunodeficiencia humana","volume":"130","author":"Miralles","year":"2008","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.medcli.2017.11.037_bib0980","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib0985","series-title":"Linfomas B y T Biolog\u00eda, Cl\u00ednica y Tratamiento","first-page":"101","article-title":"Estudio de extensi\u00f3n y estadificaci\u00f3n: factores pron\u00f3stico \u00edndices pron\u00f3stico y sistemas de clasificaci\u00f3n de los linfomas","author":"Pastor Borgo\u00f1\u00f3n","year":"2012"},{"key":"10.1016\/j.medcli.2017.11.037_bib0990","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib0995","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res."},{"key":"10.1016\/j.medcli.2017.11.037_bib1000","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1200\/JCO.1989.7.11.1630","article-title":"Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting","volume":"7","author":"Lister","year":"1989","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1005","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1002\/1097-0142(19911201)68:11<2466::AID-CNCR2820681124>3.0.CO;2-G","article-title":"Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival","volume":"68","author":"Levine","year":"1991","journal-title":"Cancer."},{"key":"10.1016\/j.medcli.2017.11.037_bib1010","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1200\/JCO.1996.14.8.2217","article-title":"Age and serum lactate dehydrogenase level are independent prognostic factors in human immunodeficiency virus-related non-Hodgkin's lymphomas: A single-institute study of 96 patients","volume":"14","author":"Vaccher","year":"1996","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1015","doi-asserted-by":"crossref","first-page":"8477","DOI":"10.1200\/JCO.2005.02.9355","article-title":"Prognostic factors in HIV-related diffuse large-cell lymphoma: Before versus after highly active antiretroviral therapy","volume":"23","author":"Lim","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1020","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1093\/annonc\/mdv036","article-title":"Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma","volume":"26","author":"Barta","year":"2015","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1025","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1002\/(SICI)1097-0142(19991201)86:11<2391::AID-CNCR29>3.0.CO;2-0","article-title":"The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma","volume":"86","author":"Rossi","year":"1999","journal-title":"Cancer."},{"key":"10.1016\/j.medcli.2017.11.037_bib1030","first-page":"508","article-title":"International prognostic index is the best prognostic factor for survival in patients with AIDS-related non-Hodgkin's lymphoma treated with CHOP. A multivariate study of 46 patients","volume":"83","author":"Navarro","year":"1998","journal-title":"Haematologica."},{"key":"10.1016\/j.medcli.2017.11.037_bib1035","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2017.11.037_bib1040","first-page":"704","article-title":"The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy","volume":"90","author":"Navarro","year":"2005","journal-title":"Haematologica."},{"key":"10.1016\/j.medcli.2017.11.037_bib1045","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1080\/10428190600658688","article-title":"Presentation and outcomes of systemic non-Hodgkin's lymphoma: A comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS","volume":"47","author":"Diamond","year":"2006","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.medcli.2017.11.037_bib1050","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/QAD.0000000000000624","article-title":"HIV-infection impact on clinical-biological features and outcome of diffuse large B-cell lymphoma treated with R-CHOP in the combination antiretroviral therapy era","volume":"29","author":"Baptista","year":"2015","journal-title":"AIDS."},{"key":"10.1016\/j.medcli.2017.11.037_bib1055","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1200\/JCO.2005.05.4684","article-title":"Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma","volume":"24","author":"Boue","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1060","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/j.1365-2141.2007.06943.x","article-title":"Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: Results of a phase II trial","volume":"140","author":"Ribera","year":"2008","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1065","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1182\/blood-2009-08-231613","article-title":"Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma","volume":"115","author":"Sparano","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib1070","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1182\/blood-2009-11-253039","article-title":"The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma","volume":"115","author":"Dunleavy","year":"2010","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib1075","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1002\/cncr.26723","article-title":"Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma","volume":"118","author":"Barta","year":"2012","journal-title":"Cancer."},{"issue":"Suppl 2","key":"10.1016\/j.medcli.2017.11.037_bib1080","first-page":"1","article-title":"British HIV Association guidelines for HIV-associated malignancies 2014","volume":"15","author":"Bower","year":"2014","journal-title":"HIV Med."},{"key":"10.1016\/j.medcli.2017.11.037_bib1085","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1182\/blood-2005-04-1437","article-title":"Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010","volume":"106","author":"Kaplan","year":"2005","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib1090","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1007\/s00277-014-2058-4","volume":"93","author":"Hentrich","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.medcli.2017.11.037_bib1095","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1002\/cncr.27396","article-title":"Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab","volume":"118","author":"Akyurek","year":"2012","journal-title":"Cancer."},{"key":"10.1016\/j.medcli.2017.11.037_bib1100","doi-asserted-by":"crossref","first-page":"e555","DOI":"10.1016\/S1470-2045(15)00005-4","article-title":"Double-hit and double-protein-expression lymphomas: Aggressive and refractory lymphomas","volume":"16","author":"Sarkozy","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1105","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Johnson","year":"2012","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1110","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Barrans","year":"2010","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1115","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bjh.12982","article-title":"Double hit lymphoma: The MD Anderson Cancer Center clinical experience","volume":"166","author":"Oki","year":"2014","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1120","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/bjh.13276","article-title":"A clinician's guide to double hit lymphomas","volume":"168","author":"Cheah","year":"2015","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1125","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: A multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib1130","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.13463","article-title":"Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: A systematic review and meta-analysis","volume":"170","author":"Howlett","year":"2015","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1135","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s11864-015-0374-0","article-title":"Aggressive B cell lymphoma: Optimal therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL","volume":"16","author":"Dunleavy","year":"2015","journal-title":"Curr Treat Options Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1140","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1200\/JCO.1996.14.3.925","article-title":"Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen","volume":"14","author":"Magrath","year":"1996","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1145","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/1042819031000141301","article-title":"Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: Preserved efficacy with decreased toxicity","volume":"45","author":"Lacasce","year":"2004","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.medcli.2017.11.037_bib1150","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/annonc\/mdf253","article-title":"An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: Results of United Kingdom Lymphoma Group LY06 study","volume":"13","author":"Mead","year":"2002","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1155","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1200\/JCO.1999.17.8.2461","article-title":"Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia","volume":"17","author":"Thomas","year":"1999","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1160","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/cncr.10365","article-title":"Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma\/leukemia","volume":"94","author":"Cortes","year":"2002","journal-title":"Cancer."},{"key":"10.1016\/j.medcli.2017.11.037_bib1165","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1002\/cncr.11628","article-title":"Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate\/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M\/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma","volume":"98","author":"Wang","year":"2003","journal-title":"Cancer."},{"key":"10.1016\/j.medcli.2017.11.037_bib1170","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1182\/blood-2006-10-051771","article-title":"Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma\/leukemia: A prospective study","volume":"110","author":"Galicier","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib1175","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/QAD.0b013e3283301578","article-title":"Excellent immunological recovery following CODOX-M\/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma","volume":"24","author":"Montoto","year":"2010","journal-title":"AIDS."},{"key":"10.1016\/j.medcli.2017.11.037_bib1180","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/cncr.21776","article-title":"Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia","volume":"106","author":"Thomas","year":"2006","journal-title":"Cancer."},{"key":"10.1016\/j.medcli.2017.11.037_bib1185","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2141.2010.08447.x","article-title":"Rituximab in combination with CODOX-M\/IVAC: A retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%","volume":"152","author":"Mohamedbhai","year":"2011","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1190","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/cncr.27918","article-title":"Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: Final results of a phase 2 study (Burkimab)","volume":"119","author":"Ribera","year":"2013","journal-title":"Cancer."},{"key":"10.1016\/j.medcli.2017.11.037_bib1195","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.3109\/10428194.2013.878933","article-title":"Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma\/leukemia: Parallel study of 81 patients","volume":"55","author":"Xicoy","year":"2014","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.medcli.2017.11.037_bib1200","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood-2015-01-623900","article-title":"AMC 048: Modified CODOX-M\/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma","volume":"126","author":"Noy","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib1205","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa1308392","article-title":"Low-intensity therapy in adults with Burkitt's lymphoma","volume":"369","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2017.11.037_bib1210","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1182\/blood-2014-10-567479","article-title":"The biology and treatment of plasmablastic lymphoma","volume":"125","author":"Castillo","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib1215","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V89.4.1413","article-title":"Plasmablastic lymphomas of the oral cavity: A new entity associated with the human immunodeficiency virus infection","volume":"89","author":"Delecluse","year":"1997","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib1220","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1002\/cncr.27551","article-title":"Human immunodeficiency virus-associated plasmablastic lymphoma: Poor prognosis in the era of highly active antiretroviral therapy","volume":"118","author":"Castillo","year":"2012","journal-title":"Cancer."},{"key":"10.1016\/j.medcli.2017.11.037_bib1225","first-page":"399","article-title":"[Plasmablastic lymphoma]","volume":"147","author":"Fernandez-Alvarez","year":"2016","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.medcli.2017.11.037_bib1230","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/ejh.12286","article-title":"CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab","volume":"93","author":"Yan","year":"2014","journal-title":"Eur J Haematol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1235","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/bjh.13300","article-title":"Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma","volume":"169","author":"Castillo","year":"2015","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1240","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2141.2007.06879.x","article-title":"KSHV\/HHV8-associated lymphomas","volume":"140","author":"Carbone","year":"2008","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1245","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1200\/JCO.2005.07.084","article-title":"Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDS","volume":"23","author":"Boulanger","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1250","article-title":"Clinical characteristics and survival outcome of primary effusion lymphoma: A review of 105 patients","author":"El-Fattah","year":"2016","journal-title":"Hematol Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1255","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1097\/00002030-199912240-00021","article-title":"AIDS-related body cavity-based lymphomas, herpesvirus-8 and HIV infection: A study of seven cases","volume":"13","author":"Valencia","year":"1999","journal-title":"AIDS."},{"key":"10.1016\/j.medcli.2017.11.037_bib1260","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2003.06.013","article-title":"Clinical features and outcome of primary effusion lymphoma in HIV-infected patients: A single-institution study","volume":"21","author":"Simonelli","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1265","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1586\/17474086.2016.1130615","article-title":"Clinical management of HIV-associated hematologic malignancies","volume":"9","author":"Wang","year":"2016","journal-title":"Expert Rev Hematol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1270","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1532\/IJH97.A30510","article-title":"Successful eradication of relapsed primary effusion lymphoma with high-dose chemotherapy and autologous stem cell transplantation in a patient seronegative for human immunodeficiency virus","volume":"83","author":"Won","year":"2006","journal-title":"Int J Hematol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1275","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1089\/108729104322802498","article-title":"Failure to eradicate AIDS-associated primary effusion lymphoma with high-dose chemotherapy and autologous stem cell reinfusion: Case report and literature review","volume":"18","author":"Waddington","year":"2004","journal-title":"AIDS Patient Care STDS."},{"key":"10.1016\/j.medcli.2017.11.037_bib1280","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.bbmt.2008.01.010","article-title":"Successful reduced-intensity conditioning allogeneic HSCT for HIV-related primary effusion lymphoma","volume":"14","author":"Bryant","year":"2008","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.medcli.2017.11.037_bib1285","doi-asserted-by":"crossref","first-page":"13069","DOI":"10.1073\/pnas.1002985107","article-title":"Efficacy of bortezomib in a direct xenograft model of primary effusion lymphoma","volume":"107","author":"Sarosiek","year":"2010","journal-title":"Proc Natl Acad Sci U S A."},{"key":"10.1016\/j.medcli.2017.11.037_bib1290","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1182\/blood.V99.7.2331","article-title":"High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease","volume":"99","author":"Oksenhendler","year":"2002","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib1295","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1093\/annonc\/mdn697","article-title":"The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease","volume":"20","author":"Powles","year":"2009","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1300","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1046\/j.1365-2141.1997.4653269.x","article-title":"Tropism of human herpesvirus 8 for peripheral blood lymphocytes in patients with Castleman's disease","volume":"99","author":"Kikuta","year":"1997","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1305","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1182\/blood-2011-02-335620","article-title":"Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease","volume":"118","author":"Stebbing","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib1310","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1200\/JCO.2007.10.6732","article-title":"Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial","volume":"25","author":"Gerard","year":"2007","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1315","doi-asserted-by":"crossref","first-page":"836","DOI":"10.7326\/0003-4819-147-12-200712180-00003","article-title":"Brief communication: Rituximab in HIV-associated multicentric Castleman disease","volume":"147","author":"Bower","year":"2007","journal-title":"Ann Intern Med."},{"key":"10.1016\/j.medcli.2017.11.037_bib1320","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1182\/blood-2011-08-376012","article-title":"Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease","volume":"119","author":"Gerard","year":"2012","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib1325","doi-asserted-by":"crossref","first-page":"2481","DOI":"10.1200\/JCO.2010.34.1909","article-title":"Clinical features and outcome in HIV-associated multicentric Castleman's disease","volume":"29","author":"Bower","year":"2011","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1330","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2169\/internalmedicine.46.6262","article-title":"Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease","volume":"46","author":"Matsuyama","year":"2007","journal-title":"Intern Med."},{"key":"10.1016\/j.medcli.2017.11.037_bib1335","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1158\/1078-0432.CCR-12-3349","article-title":"A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease","volume":"19","author":"Kurzrock","year":"2013","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.medcli.2017.11.037_bib1340","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1172\/JCI119380","article-title":"Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy","volume":"99","author":"Kedes","year":"1997","journal-title":"J Clin Invest."},{"key":"10.1016\/j.medcli.2017.11.037_bib1345","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1182\/blood-2003-05-1721","article-title":"Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment","volume":"103","author":"Casper","year":"2004","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib1350","doi-asserted-by":"crossref","first-page":"6977","DOI":"10.1182\/blood-2010-11-317610","article-title":"High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: A pilot study of virus-activated cytotoxic therapy","volume":"117","author":"Uldrick","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib1355","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1200\/JCO.2008.16.8021","article-title":"Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: A 20-year follow-up analysis of SWOG 8516 \u2014 the Southwest Oncology Group","volume":"27","author":"Bernstein","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1360","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1111\/bjh.13998","article-title":"Central nervous system involvement in AIDS-related lymphomas","volume":"173","author":"Barta","year":"2016","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1365","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3324\/haematol.11767","article-title":"Decrease in the frequency of meningeal involvement in AIDS-related systemic lymphoma in patients receiving HAART","volume":"93","author":"Navarro","year":"2008","journal-title":"Haematologica."},{"key":"10.1016\/j.medcli.2017.11.037_bib1370","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1200\/JCO.2000.18.19.3325","article-title":"Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas","volume":"18","author":"Cingolani","year":"2000","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1375","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1586\/14737140.6.3.335","article-title":"Non-Hodgkin's lymphoma and the CNS: Prophylaxis and therapy in immunocompetent and HIV-positive individuals","volume":"6","author":"Mazhar","year":"2006","journal-title":"Expert Rev Anticancer Ther."},{"key":"10.1016\/j.medcli.2017.11.037_bib1380","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.3109\/10428194.2013.869326","article-title":"Central nervous system involvement in diffuse large B-cell lymphoma: An analysis of risks and prevention strategies in the post-rituximab era","volume":"55","author":"Fletcher","year":"2014","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.medcli.2017.11.037_bib1385","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.medcli.2014.12.025","article-title":"[Central nervous system relapse in diffuse large B cell lymphoma: Risk factors]","volume":"146","author":"Sancho","year":"2016","journal-title":"Med Clin (Barc)."},{"key":"10.1016\/j.medcli.2017.11.037_bib1390","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.blre.2006.02.001","article-title":"CNS prophylaxis in lymphoma: Who to target and what therapy to use","volume":"20","author":"Hill","year":"2006","journal-title":"Blood Rev."},{"key":"10.1016\/j.medcli.2017.11.037_bib1395","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1002\/cncr.25278","article-title":"Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma","volume":"116","author":"Abramson","year":"2010","journal-title":"Cancer."},{"key":"10.1016\/j.medcli.2017.11.037_bib1400","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/annonc\/mds621","article-title":"Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell\/follicular grade 3 lymphoma patients: Results of a phase II Nordic Lymphoma Group study","volume":"24","author":"Holte","year":"2013","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1405","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.1999.17.10.3110","article-title":"Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis","volume":"17","author":"Glantz","year":"1999","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1410","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1182\/blood-2005-08-3119","article-title":"The management of meningeal lymphoma in patients with HIV in the era of HAART: Intrathecal depot cytarabine is effective and safe","volume":"107","author":"Mazhar","year":"2006","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib1415","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2006-08-043646","article-title":"Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia","volume":"109","author":"Jabbour","year":"2007","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib1420","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.1994.12.6.1169","article-title":"ESHAP\u2014an effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study","volume":"12","author":"Velasquez","year":"1994","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1425","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1182\/blood-2008-12-195388","article-title":"Comparable survival between HIV+ and HIV\u2212 non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation","volume":"113","author":"Diez-Martin","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib1430","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1182\/blood-2015-08-664706","article-title":"Autologous hematopoietic cell transplantation for HIV-related lymphoma: Results of the BMT CTN 0803\/AMC 071 trial","volume":"128","author":"Alvarnas","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib1435","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.3109\/10428194.2012.697559","article-title":"Outcome of patients with relapsed\/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium","volume":"53","author":"Bayraktar","year":"2012","journal-title":"Leuk Lymphoma."},{"key":"10.1016\/j.medcli.2017.11.037_bib1440","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/00002030-200307040-00013","article-title":"Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma","volume":"17","author":"Hoffmann","year":"2003","journal-title":"AIDS."},{"key":"10.1016\/j.medcli.2017.11.037_bib1445","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1200\/JCO.2005.11.973","article-title":"AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: Significant differences in survival with standard chemotherapy","volume":"23","author":"Lim","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1450","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1046\/j.1365-2141.2001.02656.x","article-title":"Influence of highly active anti-retroviral therapy on response to treatment and survival in patients with acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma treated with cyclophosphamide, hydroxydoxorubicin, vincristine and prednisone","volume":"112","author":"Navarro","year":"2001","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1455","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/1097-0142(20010101)91:1<155::AID-CNCR20>3.0.CO;2-B","article-title":"Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma","volume":"91","author":"Vaccher","year":"2001","journal-title":"Cancer."},{"key":"10.1016\/j.medcli.2017.11.037_bib1460","doi-asserted-by":"crossref","first-page":"O672","DOI":"10.1111\/1469-0691.12589","article-title":"Efficacy and safety of antiretrovirals in HIV-infected patients with cancer","volume":"20","author":"Torres","year":"2014","journal-title":"Clin Microbiol Infect."},{"key":"10.1016\/j.medcli.2017.11.037_bib1465","first-page":"340","article-title":"[Prevalences of hepatitis virus coinfection and indications for chronic hepatitis C virus treatment and liver transplantation in Spanish HIV-infected patients. The GESIDA 29\/02 and FIPSE 12185\/01 Multicenter Study]","volume":"23","author":"Gonzalez-Garcia","year":"2005","journal-title":"Enferm Infecc Microbiol Clin."},{"key":"10.1016\/j.medcli.2017.11.037_bib1470","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.aids.0000163936.99401.fe","article-title":"Hepatitis B and HIV: Prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort","volume":"19","author":"Konopnicki","year":"2005","journal-title":"AIDS."},{"key":"10.1016\/j.medcli.2017.11.037_bib1475","doi-asserted-by":"crossref","first-page":"ofw059","DOI":"10.1093\/ofid\/ofw059","article-title":"Human immunodeficiency virus\/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics","volume":"3","author":"Berenguer","year":"2016","journal-title":"Open Forum Infect Dis."},{"key":"10.1016\/j.medcli.2017.11.037_bib1480","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1182\/blood-2003-12-4222","article-title":"Hepatitis B reactivation during combination chemotherapy for AIDS-related lymphoma is uncommon and does not adversely affect outcome","volume":"103","author":"Stebbing","year":"2004","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib1485","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1365-2141.2006.06465.x","article-title":"Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies","volume":"136","author":"Lalazar","year":"2007","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1490","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","article-title":"Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: Meta-analysis and examination of FDA safety reports","volume":"22","author":"Evens","year":"2011","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1495","doi-asserted-by":"crossref","first-page":"e68152","DOI":"10.1371\/journal.pone.0068152","article-title":"Suppression of HBV by tenofovir in HBV\/HIV coinfected patients: A systematic review and meta-analysis","volume":"8","author":"Price","year":"2013","journal-title":"PLoS One."},{"key":"10.1016\/j.medcli.2017.11.037_bib1500","unstructured":"Panel de expertos de GeSIDA y Plan Nacional sobre el Sida. Documento de consenso de GeSIDA\/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infecta- dos por el virus de la inmunodeficiencia humana [actualizaci\u00f3n enero 2017]. Disponible en: http:\/\/gesida-seimc.org\/wp-content\/uploads\/2017\/02\/gesida-guiasclinicas-2017-TAR.pdf"},{"key":"10.1016\/j.medcli.2017.11.037_bib1505","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: A randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1510","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase3, non-inferiority trial","volume":"1","author":"Chan","year":"2016","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1515","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1097\/QAD.0000000000000623","article-title":"Adding rituximab to CODOX-M\/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy","volume":"29","author":"Alwan","year":"2015","journal-title":"AIDS."},{"key":"10.1016\/j.medcli.2017.11.037_bib1520","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1182\/blood-2004-05-1747","article-title":"Protease inhibitors potentiate chemotherapy-induced neutropenia","volume":"104","author":"Bower","year":"2004","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib1525","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1182\/blood-2013-04-498964","article-title":"Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: A pooled analysis of 1546 patients","volume":"122","author":"Barta","year":"2013","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib1530","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S1470-2045(11)70056-0","article-title":"Use of antineoplastic agents in patients with cancer who have HIV\/AIDS","volume":"12","author":"Rudek","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1535","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1681\/ASN.2012080857","article-title":"Tenofovir effect on the kidneys of HIV-infected patients: A double-edged sword?","volume":"24","author":"Tourret","year":"2013","journal-title":"J Am Soc Nephrol."},{"issue":"Suppl 2","key":"10.1016\/j.medcli.2017.11.037_bib1540","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/hiv.12401","article-title":"The role of tenofovir alafenamide in future HIV management","volume":"17","author":"Antela","year":"2016","journal-title":"HIV Med."},{"key":"10.1016\/j.medcli.2017.11.037_bib1545","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1182\/blood.V97.10.2998","article-title":"A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis","volume":"97","author":"Goldman","year":"2001","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib1550","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1200\/JCO.2001.19.3.697","article-title":"Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma","volume":"19","author":"Pui","year":"2001","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1555","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","article-title":"2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1560","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.eimc.2016.02.025","article-title":"Executive summary: Prevention and treatment of opportunistic infections and other coinfections in HIV-infected patients: May 2015","volume":"34","author":"Iribarren","year":"2016","journal-title":"Enferm Infecc Microbiol Clin."},{"key":"10.1016\/j.medcli.2017.11.037_bib1565","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.medcli.2017.11.037_bib1570","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.medcli.2017.11.037_bib1575","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1200\/JCO.2012.45.8661","article-title":"Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline","volume":"31","author":"Flowers","year":"2013","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1580","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1093\/infdis\/jis487","article-title":"Influenza vaccination for immunocompromised patients: Systematic review and meta-analysis by etiology","volume":"206","author":"Beck","year":"2012","journal-title":"J Infect Dis."},{"key":"10.1016\/j.medcli.2017.11.037_bib1585","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.medcli.2017.11.037_bib1590","unstructured":"Ministerio de Sanidad Servicios Sociales e Igualdad. Vacunaci\u00f3n en Adultos. Recomendaciones. A\u00f1o 2004. Disponible en: https:\/\/www.msssi.gob.es\/ciudadanos\/proteccionSalud\/vacunaciones\/docs\/recoVacunasAdultos.pdf"},{"key":"10.1016\/j.medcli.2017.11.037_bib1595","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.hoc.2005.05.004","article-title":"AIDS-related primary central nervous system lymphoma","volume":"19","author":"Kasamon","year":"2005","journal-title":"Hematol Oncol Clin North Am."},{"key":"10.1016\/j.medcli.2017.11.037_bib1600","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/00002142-199904000-00003","article-title":"Clinical applications of proton magnetic resonance spectroscopy in the evaluation of common intracranial tumors","volume":"10","author":"Castillo","year":"1999","journal-title":"Top Magn Reson Imaging."},{"key":"10.1016\/j.medcli.2017.11.037_bib1605","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1148\/radiology.197.3.7480733","article-title":"Toxoplasmosis and primary central nervous system lymphoma in HIV infection: Diagnosis with MR spectroscopy","volume":"197","author":"Chinn","year":"1995","journal-title":"Radiology."},{"key":"10.1016\/j.medcli.2017.11.037_bib1610","first-page":"1366","article-title":"Thallium-201 retention in focal intracranial lesions for differential diagnosis of primary lymphoma and nonmalignant lesions in AIDS patients","volume":"39","author":"Lorberboym","year":"1998","journal-title":"J Nucl Med."},{"key":"10.1016\/j.medcli.2017.11.037_bib1615","first-page":"818","article-title":"Utility of brain FDG-PET in primary CNS lymphoma","volume":"6","author":"Mohile","year":"2008","journal-title":"Clin Adv Hematol Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1620","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s004310050813","article-title":"Epstein-Barr virus DNA in the cerebrospinal fluid of an HIV patient with primary cerebral lymphoma","volume":"157","author":"Plebani","year":"1998","journal-title":"Eur J Pediatr."},{"key":"10.1016\/j.medcli.2017.11.037_bib1625","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/0140-6736(93)92814-A","article-title":"Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system","volume":"342","author":"Cinque","year":"1993","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2017.11.037_bib1630","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/BF00812158","article-title":"Stereotactic brain biopsy in AIDS","volume":"239","author":"Zimmer","year":"1992","journal-title":"J Neurol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1635","doi-asserted-by":"crossref","DOI":"10.1016\/j.wneu.2016.11.151","article-title":"Diagnostic value and safety of stereotactic biopsy in acquired immune deficiency syndrome patients with intracranial lesions: Systematic review and meta-analysis","volume":"98","author":"Zhang","year":"2017","journal-title":"World Neurosurg."},{"key":"10.1016\/j.medcli.2017.11.037_bib1640","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0360-3016(92)90538-S","article-title":"Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315","volume":"23","author":"Nelson","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.medcli.2017.11.037_bib1645","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00005792-199011000-00003","article-title":"Primary central nervous system lymphoma in patients with and without the acquired immune deficiency syndrome. A retrospective analysis and review of the literature","volume":"69","author":"Remick","year":"1990","journal-title":"Medicine (Baltimore)."},{"key":"10.1016\/j.medcli.2017.11.037_bib1650","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3171\/jns.1990.73.2.0206","article-title":"Primary central nervous system lymphomas: Natural history and response to radiation therapy in 55 patients with acquired immunodeficiency syndrome","volume":"73","author":"Baumgartner","year":"1990","journal-title":"J Neurosurg."},{"key":"10.1016\/j.medcli.2017.11.037_bib1655","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1002\/1097-0142(19910601)67:11<2756::AID-CNCR2820671108>3.0.CO;2-3","article-title":"Primary central nervous system lymphoma in acquired immune deficiency syndrome. A clinical and pathologic study with results of treatment with radiation","volume":"67","author":"Goldstein","year":"1991","journal-title":"Cancer."},{"key":"10.1016\/j.medcli.2017.11.037_bib1660","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1097\/00002030-200111090-00007","article-title":"Survival of AIDS patients with primary central nervous system lymphoma is dramatically improved by HAART-induced immune recovery","volume":"15","author":"Hoffmann","year":"2001","journal-title":"AIDS."},{"key":"10.1016\/j.medcli.2017.11.037_bib1665","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1200\/JCO.2003.03.108","article-title":"High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962","volume":"21","author":"Poortmans","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1670","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1200\/JCO.1998.16.3.864","article-title":"High-dose methotrexate for the treatment of primary cerebral lymphomas: Analysis of survival and late neurologic toxicity in a retrospective series","volume":"16","author":"Blay","year":"1998","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1675","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1200\/JCO.2002.11.013","article-title":"Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10","volume":"20","author":"DeAngelis","year":"2002","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1680","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s11060-004-6596-9","article-title":"Secondary analysis of Radiation Therapy Oncology Group study (RTOG) 9310 an intergroup phase II combined modality treatment of primary central nervous system lymphoma","volume":"74","author":"Fisher","year":"2005","journal-title":"J Neurooncol"},{"key":"10.1016\/j.medcli.2017.11.037_bib1685","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S1470-2045(10)70229-1","article-title":"High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): A phase 3, randomised, non-inferiority trial","volume":"11","author":"Thiel","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1690","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1212\/WNL.44.8.1473","article-title":"Combined-modality therapy in the treatment of primary central nervous system lymphoma in AIDS","volume":"44","author":"Forsyth","year":"1994","journal-title":"Neurology."},{"key":"10.1016\/j.medcli.2017.11.037_bib1695","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.2003.03.036","article-title":"Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: A report of NABTT 96-07","volume":"21","author":"Batchelor","year":"2003","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1700","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/S0140-6736(09)61416-1","article-title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: A randomised phase 2 trial","volume":"374","author":"Ferreri","year":"2009","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2017.11.037_bib1705","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/neuonc\/now155","article-title":"Long-term survival in AIDS-related primary central nervous system lymphoma","volume":"19","author":"Gupta","year":"2017","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1710","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1097\/00002030-199714000-00009","article-title":"Intravenous methotrexate for primary central nervous system non-Hodgkin's lymphoma in AIDS","volume":"11","author":"Jacomet","year":"1997","journal-title":"AIDS."},{"key":"10.1016\/j.medcli.2017.11.037_bib1715","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/neuonc\/not032","article-title":"Rituximab is associated with improved survival for aggressive B cell CNS lymphoma","volume":"15","author":"Gregory","year":"2013","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1720","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.bmt.1705452","article-title":"High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: A multicenter phase II study of the GOELAMS group","volume":"38","author":"Colombat","year":"2006","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.medcli.2017.11.037_bib1725","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/annonc\/mdr553","volume":"23","author":"Kiefer","year":"2012","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1730","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1093\/annonc\/mds059","article-title":"Prognosis after high-dose chemotherapy followed by autologous stem-cell transplantation as first-line treatment in primary CNS lymphoma\u2014a long-term follow-up study","volume":"23","author":"Kasenda","year":"2012","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1735","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1182\/blood-2015-10-636340","article-title":"The role of autologous stem cell transplantation in primary central nervous system lymphoma","volume":"127","author":"Ferreri","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib1740","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/QAI.0b013e31815e722b","article-title":"Characteristics and outcome of AIDS-related Hodgkin lymphoma before and after the introduction of highly active antiretroviral therapy","volume":"47","author":"Berenguer","year":"2008","journal-title":"J Acquir Immune Defic Syndr."},{"key":"10.1016\/j.medcli.2017.11.037_bib1745","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3324\/haematol.10479","article-title":"Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma","volume":"92","author":"Xicoy","year":"2007","journal-title":"Haematologica."},{"key":"10.1016\/j.medcli.2017.11.037_bib1750","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1200\/JCO.2011.41.4193","article-title":"HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era","volume":"30","author":"Montoto","year":"2012","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1755","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1158\/1055-9965.EPI-14-1079","article-title":"Survival among HIV-infected and HIV-uninfected individuals with common non-AIDS-defining cancers","volume":"24","author":"Marcus","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"10.1016\/j.medcli.2017.11.037_bib1760","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin's disease International Prognostic Factors Project on Advanced Hodgkin's Disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2017.11.037_bib1765","first-page":"325","article-title":"Usefulness of the prognostic score for advanced Hodgkin's disease in patients with human immunodeficiency virus-associated Hodgkin's lymphoma","volume":"85","author":"Ribera","year":"2000","journal-title":"Haematologica."},{"key":"10.1016\/j.medcli.2017.11.037_bib1770","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/cncr.29066","article-title":"Prognostic factors for advanced-stage human immunodeficiency virus-associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus combined antiretroviral therapy: A multi-institutional retrospective study","volume":"121","author":"Castillo","year":"2015","journal-title":"Cancer."},{"key":"10.1016\/j.medcli.2017.11.037_bib1775","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1182\/blood-2002-03-0989","article-title":"Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection","volume":"100","author":"Spina","year":"2002","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib1780","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1093\/annonc\/mdg408","article-title":"BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection","volume":"14","author":"Hartmann","year":"2003","journal-title":"Ann Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1785","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.1200\/JCO.2012.41.8137","article-title":"Stage-adapted treatment of HIV-associated Hodgkin lymphoma: Results of a prospective multicenter study","volume":"30","author":"Hentrich","year":"2012","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1790","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/bjh.12878","article-title":"Guidelines for the first line management of classical Hodgkin lymphoma","volume":"166","author":"Follows","year":"2014","journal-title":"Br J Haematol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1795","doi-asserted-by":"crossref","first-page":"16","DOI":"10.6004\/jnccn.2014.0003","article-title":"Brentuximab vedotin in patients with relapsed HIV-related lymphoma","volume":"12","author":"Gandhi","year":"2014","journal-title":"J Natl Compr Canc Netw."},{"key":"10.1016\/j.medcli.2017.11.037_bib1800","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2017.11.037_bib1805","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0140-6736(00)02041-9","article-title":"High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphoma","volume":"355","author":"Gabarre","year":"2000","journal-title":"Lancet."},{"key":"10.1016\/j.medcli.2017.11.037_bib1810","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.exphem.2004.12.008","article-title":"HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation","volume":"33","author":"Serrano","year":"2005","journal-title":"Exp Hematol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1815","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1182\/blood-2004-04-1532","article-title":"Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas","volume":"105","author":"Krishnan","year":"2005","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib1820","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1200\/JCO.2008.18.2683","article-title":"Autologous stem-cell transplantation in patients with HIV-related lymphoma","volume":"27","author":"Balsalobre","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1825","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1182\/blood-2009-02-202762","article-title":"High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: Long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors","volume":"114","author":"Re","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.medcli.2017.11.037_bib1830","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1200\/JCO.2015.61.1236","article-title":"High doses of antimetabolites followed by high-dose sequential chemoimmunotherapy and autologous stem-cell transplantation in patients with systemic B-cell lymphoma and secondary CNS involvement: Final results of a multicenter phase II trial","volume":"33","author":"Ferreri","year":"2015","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1835","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.bbmt.2009.03.023","article-title":"Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic disorders: A report from the center for international blood and marrow transplant research","volume":"15","author":"Gupta","year":"2009","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.medcli.2017.11.037_bib1840","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMoa0802905","article-title":"Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation","volume":"360","author":"Hutter","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medcli.2017.11.037_bib1845","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2249.2010.04312.x","article-title":"Allogeneic haematopoietic stem cell transplantation in patients with human immunodeficiency virus: The experiences of more than 25years","volume":"163","author":"Hutter","year":"2011","journal-title":"Clin Exp Immunol."},{"key":"10.1016\/j.medcli.2017.11.037_bib1850","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1089\/aid.2013.0001","article-title":"Graft-versus-tumor effect after allogeneic stem cell transplantation in HIV-positive patients with high-risk hematologic malignancies","volume":"29","author":"Serrano","year":"2013","journal-title":"AIDS Res Hum Retroviruses."},{"key":"10.1016\/j.medcli.2017.11.037_bib1855","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/infdis\/jit086","article-title":"Long-term reduction in peripheral blood HIV type1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation","volume":"207","author":"Henrich","year":"2013","journal-title":"J Infect Dis."},{"key":"10.1016\/j.medcli.2017.11.037_bib1860","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.bbmt.2015.08.006","article-title":"Safety and efficacy of combination antiretroviral therapy in human immunodeficiency virus-infected adults undergoing autologous or allogeneic hematopoietic cell transplantation for hematologic malignancies","volume":"22","author":"Johnston","year":"2016","journal-title":"Biol Blood Marrow Transplant."}],"container-title":["Medicina Cl\u00ednica"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775317309211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025775317309211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T16:19:49Z","timestamp":1719764389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025775317309211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":186,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0025775317309211"],"URL":"https:\/\/doi.org\/10.1016\/j.medcli.2017.11.037","relation":{},"ISSN":["0025-7753"],"issn-type":[{"value":"0025-7753","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recomendaciones de GESIDA\/PETHEMA sobre el diagn\u00f3stico y tratamiento de los linfomas en pacientes infectados por el virus de la inmunodeficiencia humana","name":"articletitle","label":"Article Title"},{"value":"Medicina Cl\u00ednica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medcli.2017.11.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}